Udvalget konkluderede først, at fordelene ved Exelon ikke opvejer risiciene til behandling af demens ved Parkinsons sygdom.
The Committee initially concluded that for the treatment of dementia due to Parkinson’ s disease, Exelon’ s benefits did not outweigh its risks.